- R-(-)-Apomorphine
-
- $11500.00 / 10kilograms
-
2026-02-25
- CAS:41372-20-7
- Min. Order: 10kilograms
- Purity: 99%
- Supply Ability: 100tons
- R-(-)-Apomorphine
-
- $10.00 / 1kg
-
2023-06-30
- CAS:41372-20-7
- Min. Order: 1kg
- Purity: 99.99%
- Supply Ability: 50000tons
|
| | R-(-)-Apomorphine Basic information |
| Product Name: | R-(-)-Apomorphine | | Synonyms: | (r)-5,6,6a,7-tetrahydro-6-methyl-4h-dibenzo[de,g]quinoline-10,11-diol;Apomorphine hydrochloride R-(-)-;(6Ar)-5,6,6A,7-tetrahydro-6-methyl-4H-dibenzo(de,G)chinolin-10,11-diol hydrochlorid;6a-beta-aporphine-10,11-diol;APOMORPHINE HYDROCHLORIDE, HEMIHYDRATE;4H-Dibenzode,gquinoline-10,11-diol, 5,6,6a,7-tetrahydro-6-methyl-, hydrochloride, hydrate (2:1), (6aR)-;APOMORPHINEHCLHEMIHYDRATE;APOMORPHINEHYDROCHLORIDE,HEMIHYDRATE,USP | | CAS: | 41372-20-7 | | MF: | C17H20ClNO3 | | MW: | 321.8 | | EINECS: | 627-402-4 | | Product Categories: | Inhibitors;APOKYN;Chiral Reagents;Heterocycles;Intermediates & Fine Chemicals;Pharmaceuticals;Agonists;Dopaminergics;Neurotransmitters;Erectile Dysfunction;Dopamine receptor | | Mol File: | 41372-20-7.mol |  |
| | R-(-)-Apomorphine Chemical Properties |
| Melting point | 285-287 °C(lit.) | | alpha | -48 º (c=1, H2O) | | storage temp. | Refrigerator | | solubility | H2O: ~10 mg/mL, clear, yellow-green | | form | Solid | | color | white to gray | | PH | pH(10g/l, 25℃) : 4.0～5.0 | | Water Solubility | H2O: ~10mg/mL, clear, yellow-green | | Merck | 13,751 | | Stability: | Stable for 1 year from date of purchase as supplied. Solutions in distilled water may be stored at -20°C for up to 1 week. | | InChI | 1S/2C17H17NO2.2ClH.H2O/c2*1-18-8-7-10-3-2-4-12-15(10)13(18)9-11-5-6-14(19)17(20)16(11)12;;;/h2*2-6,13,19-20H,7-9H2,1H3;2*1H;1H2/t2*13-;;;/m11.../s1 | | InChIKey | CXWQXGNFZLHLHQ-DPFCLETOSA-N | | SMILES | Cl[H].Cl[H].[H]O[H].[H][C@]12Cc3ccc(O)c(O)c3-c4cccc(CCN1C)c24.[H][C@]56Cc7ccc(O)c(O)c7-c8cccc(CCN5C)c68 | | CAS DataBase Reference | 41372-20-7(CAS DataBase Reference) |
| Hazard Codes | Xn | | Risk Statements | 22 | | Safety Statements | 36 | | RIDADR | UN 2811 6.1/PG 3 | | WGK Germany | 3 | | HS Code | 2933997000 | | Storage Class | 6.1C - Combustible acute toxic Cat.3
toxic compounds or compounds which causing chronic effects | | Hazard Classifications | Acute Tox. 3 Oral |
| | R-(-)-Apomorphine Usage And Synthesis |
| Description | Apomorphine (41372-20-7) is an archetypal dopamine pan-receptor agonist. Displays anti-Parkinsons activity in vivo.1 Protects against MPTP-induced neurotoxicity in a mouse mode1,2 In clinical use for Parkinson’s disease.4,5 | | Chemical Properties | Off-White Solid | | Uses | emetic, antiparkinsonian, erextile dysfunction therapy | | Uses | Dopamine (D1 and D2) receptor agonist. Emetic. Antiparkinsonian. | | Uses | R-()-Apomorphine hydrochloride hemihydrate is a nonselective dopamine agonist with anti-Parkinsonian and neuroprotective effects in vivo. | | Brand name | Apokyn
(Vernalis). | | Purification Methods | Crystallise the salt from H2O (hemihydrate) and from EtOH. Crystals turn green on exposure to light. (see previous entry). NARCOTIC. | | References | [1] Merck’s Index, Nachtrag 1930. Verlag von E. Merck, Darmstadt. 14 Seiten[J]. Archiv der Pharmazie, 1930, 268 6: 444-445. DOI:10.1002/ardp.19302680608
[2] MARK J MILLAN. Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes.[J]. Journal of Pharmacology and Experimental Therapeutics, 2002, 303 2: 791-804. DOI:10.1124/jpet.102.039867
[3] EDNA GRÜNBLATT DSC (STUDENT). Apomorphine protects against MPTP-induced neurotoxicity in mice[J]. Movement Disorders, 2001, 14 4: 612-618. DOI:10.1002/1531-8257(199907)14:4<612::aid-mds1010>3.0.co;2-6
[4] MANON AUFFRET . Apomorphine pump in advanced Parkinson’s disease: Effects on motor and nonmotor symptoms with brain metabolism correlations[J]. Journal of the Neurological Sciences, 2017, 372: Pages 279-287. DOI:10.1016/j.jns.2016.11.080
[5] PETER JENNER Regina K. Apomorphine - pharmacological properties and clinical trials in Parkinson’s disease[J]. Parkinsonism & related disorders, 2016, 33: Pages S13-S21. DOI:10.1016/j.parkreldis.2016.12.003 |
| | R-(-)-Apomorphine Preparation Products And Raw materials |
|